Drug Manufacturing Sector Scorecard - Thematic Intelligence

Pharma manufacturing and supply chains need to be sustainable and resilient in today's geopolitical and macroeconomic landscape: Pharma supply chains are complex processes through which drugs are developed, manufactured, and delivered to patients. Outsourced manufacturing is a key supply chain component and is being driven by increased drug consumption and the development of more advanced treatments. Pharma is under increasing pressure to ensure supply chain sustainability and resilience. Environmentally sustainable supply chains and manufacturing involve reducing greenhouse gases, improving air quality and water management, and more renewable energy usage. Social sustainability ensures that patients get access to drugs and promotes employee health and safety, human rights, and ethics. COVID-19, the war in Ukraine, and rising raw material and fuel costs are leading to concerns about supply chain sustainability and resilience.

Pharma must invest in smart technologies for more efficient and secure drug manufacturing: COVID-19 forced many companies to accelerate digital transformation and implement technology-fueled changes to their operations. Smart technologies, such as robotics, AI, big data analytics, cloud computing, and blockchain offer the industry the ability to increase efficiencies, create agile operational models, and innovate processes within its value chain, such as allowing for fully digitized drug manufacturing. Companies that embrace smart technologies will be better positioned to gain a competitive advantage and reduce financial risks.

Scope

• The publisher's Drug Manufacturing Thematic Scorecard report provides a top-down, comprehensive future outlook for key players in the drug manufacturing sector over the next two to four years.
• These themes are Supply Chain Management, Foreign Direct Investment (FDI), Deal Making, ESG, Robotics, AI, Big Data, Cloud Computing, Cybersecurity, and Blockchain
• The scorecard includes 51 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, and contract development and manufacturing organizations (CDMOs).
• It is important to note that this scorecard is not an assessment of current performance of a company in a theme, but a view of future performance based on current levels of activity and investment.
• The methodology section contains information on what data sources were used to generate the thematic scores for each company.
• The scorecard is live on the PIC and will be updated quarterly.

Reasons to Buy

• Identify the key drug manufacturing themes for the next 2-4 years and learn how they will impact the market.
• Understand which key themes should be addressed to drive share price.
• Understand which companies are best positioned for success within critical themes and why.
• Learn which companies have underinvested in key themes and are most vulnerable to disruption.
• Help companies adapt their strategy to anticipate and benefit from these themes as they play out.
• Help identify future winners and losers in drug manufacturing to inform partnership strategies.